Press Releases

09.14.2022

Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022

09.14.2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

09.12.2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

09.09.2022

FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata

09.07.2022

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

09.06.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.06.2022

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action

09.01.2022

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

09.01.2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

08.31.2022

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

08.26.2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

08.25.2022

Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate